Image (Image 01)
Diltiazem Hydrochloride Capsule, Extended Release
Product Images NDC 71335-2602
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Diltiazem Hydrochloride (NDC 71335-2602). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (Image 02)
This text provides data on the comparison between adverse reactions observed in patients taking Diltiazem hydrochloride extended-release capsules versus a placebo in placebo-controlled angina and hypertension trials combined. Some of the adverse reactions listed include headache, dizziness, bradycardia, AV block, edema, and asthenia. The table displays the percentage of patients experiencing each reaction for both the Diltiazem hydrochloride group and the placebo group.*
Label (Lbl713352602)
Each extended-release capsule contains Diltiazem Hydrochloride, USP 180 mg. It is equivalent to 165.45 mg Diltiazem. These capsules should be stored at 20° to 25° C (68° to 77° F) with excursions permitted to 15° to 30° C (59° to 86° F). They should be kept out of the reach of children. This medication can cause dizziness or drowsiness, and it is recommended to protect it from moisture. The capsules come in a package of 30, indicated for Rx only.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
